000136364 001__ 136364
000136364 005__ 20240321220044.0
000136364 0247_ $$2doi$$a10.1016/j.sleep.2011.06.016
000136364 0247_ $$2pmid$$apmid:22063473
000136364 0247_ $$2ISSN$$a1389-9457
000136364 0247_ $$2ISSN$$a1878-5506
000136364 037__ $$aDZNE-2020-02686
000136364 041__ $$aEnglish
000136364 082__ $$a610
000136364 1001_ $$aSzentkiralyi, Andras$$b0
000136364 245__ $$aIncidence of restless legs syndrome in two population-based cohort studies in Germany.
000136364 260__ $$aAmsterdam [u.a.]$$bElsevier$$c2011
000136364 264_1 $$2Crossref$$3print$$bElsevier BV$$c2011-10-01
000136364 3367_ $$2DRIVER$$aarticle
000136364 3367_ $$2DataCite$$aOutput Types/Journal article
000136364 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1710772913_18974
000136364 3367_ $$2BibTeX$$aARTICLE
000136364 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000136364 3367_ $$00$$2EndNote$$aJournal Article
000136364 520__ $$aProspective data about the new-onset of restless legs syndrome (RLS) are lacking. Our aim was to assess the incidence rate of RLS in the general population.MethodsRLS, defined by the minimal diagnostic criteria, was assessed twice in two independently conducted prospective population-based cohort studies in Germany. The Dortmund Health Study (DHS) had a mean follow-up of 2.2 years, and included 1312 participants, and the Study of Health in Pomerania (SHIP) followed 4308 participants for, on average, 5.2 years. RLS was assessed during face-to-face interviews in both studies at baseline and at follow-up in SHIP, and with mailed questionnaires at follow-up in DHS.ResultsThe age-standardized incidence rate of RLS was 22/1000 person-years (p-y) (cumulative incidence over the follow-up: 9.1%) in DHS and 9/1000 p-y (cumulative incidence: 7.0%) in SHIP. Women had a higher incidence rate than men (DHS: 27/1000 p-y vs. 17/1000 p-y, p = 0.28; SHIP: 12/1000 p-y vs. 7/1000 p-y, p < 0.001). There was a linear increase in RLS incidence rate with age in both studies. The persistence of RLS symptoms from baseline to follow-up was 47.4% in DHS and 41.5% in SHIP.ConclusionThe incidence rate of RLS is high, while the persistence of RLS over time is low, suggesting that RLS symptoms vary considerably. The increased RLS incidence rate among women and the elderly is consistent with previous prevalence data.
000136364 536__ $$0G:(DE-HGF)POF3-344$$a344 - Clinical and Health Care Research (POF3-344)$$cPOF3-344$$fPOF III$$x0
000136364 542__ $$2Crossref$$i2011-10-01$$uhttps://www.elsevier.com/tdm/userlicense/1.0/
000136364 588__ $$aDataset connected to CrossRef, PubMed,
000136364 650_2 $$2MeSH$$aAdult
000136364 650_2 $$2MeSH$$aAge Distribution
000136364 650_2 $$2MeSH$$aAged
000136364 650_2 $$2MeSH$$aCohort Studies
000136364 650_2 $$2MeSH$$aComorbidity
000136364 650_2 $$2MeSH$$aFemale
000136364 650_2 $$2MeSH$$aFollow-Up Studies
000136364 650_2 $$2MeSH$$aGermany: epidemiology
000136364 650_2 $$2MeSH$$aHumans
000136364 650_2 $$2MeSH$$aIncidence
000136364 650_2 $$2MeSH$$aMale
000136364 650_2 $$2MeSH$$aMiddle Aged
000136364 650_2 $$2MeSH$$aPrevalence
000136364 650_2 $$2MeSH$$aProspective Studies
000136364 650_2 $$2MeSH$$aRestless Legs Syndrome: epidemiology
000136364 650_2 $$2MeSH$$aSex Distribution
000136364 650_2 $$2MeSH$$aSurveys and Questionnaires
000136364 7001_ $$0P:(DE-2719)9000968$$aFendrich, Konstanze$$b1$$udzne
000136364 7001_ $$0P:(DE-2719)2000040$$aHoffmann, Wolfgang$$b2$$udzne
000136364 7001_ $$aHappe, Svenja$$b3
000136364 7001_ $$0P:(DE-HGF)0$$aBerger, Klaus$$b4$$eCorresponding author
000136364 77318 $$2Crossref$$3journal-article$$a10.1016/j.sleep.2011.06.016$$b : Elsevier BV, 2011-10-01$$n9$$p815-820$$tSleep Medicine$$v12$$x1389-9457$$y2011
000136364 773__ $$0PERI:(DE-600)2041737-8$$a10.1016/j.sleep.2011.06.016$$gVol. 12, no. 9, p. 815 - 820$$n9$$p815-820$$q12:9<815 - 820$$tSleep medicine$$v12$$x1389-9457$$y2011
000136364 8564_ $$uhttps://pub.dzne.de/record/136364/files/DZNE-2020-02686_Restricted.pdf
000136364 8564_ $$uhttps://pub.dzne.de/record/136364/files/DZNE-2020-02686_Restricted.pdf?subformat=pdfa$$xpdfa
000136364 909CO $$ooai:pub.dzne.de:136364$$pVDB
000136364 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)9000968$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b1$$kDZNE
000136364 9101_ $$0I:(DE-588)1065079516$$6P:(DE-2719)2000040$$aDeutsches Zentrum für Neurodegenerative Erkrankungen$$b2$$kDZNE
000136364 9131_ $$0G:(DE-HGF)POF3-344$$1G:(DE-HGF)POF3-340$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lErkrankungen des Nervensystems$$vClinical and Health Care Research$$x0
000136364 9141_ $$y2011
000136364 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bSLEEP MED : 2017
000136364 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000136364 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000136364 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000136364 915__ $$0StatID:(DE-HGF)0600$$2StatID$$aDBCoverage$$bEbsco Academic Search
000136364 915__ $$0StatID:(DE-HGF)0030$$2StatID$$aPeer Review$$bASC
000136364 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000136364 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000136364 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000136364 915__ $$0StatID:(DE-HGF)9900$$2StatID$$aIF < 5
000136364 9201_ $$0I:(DE-2719)6000020$$kWitten common$$lWitten common$$x0
000136364 9201_ $$0I:(DE-2719)1510600$$kAG Hoffmann$$lTranslational Health Care Research$$x1
000136364 980__ $$ajournal
000136364 980__ $$aVDB
000136364 980__ $$aI:(DE-2719)6000020
000136364 980__ $$aI:(DE-2719)1510600
000136364 980__ $$aUNRESTRICTED